Seeking Alpha

Bad news for Orexigen (OREX -38%) and its Contrave obesity drug: Regulators "requested a...

Bad news for Orexigen (OREX -38%) and its Contrave obesity drug: Regulators "requested a pre-approval cardiovascular outcomes trial that OREX believes is unprecedented and would generate significantly more information than is necessary or feasible." Regulators also won't consider approving Contrave for a narrowed population without first reviewing data from the trial. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|